MX2016008729A - Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. - Google Patents

Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.

Info

Publication number
MX2016008729A
MX2016008729A MX2016008729A MX2016008729A MX2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A
Authority
MX
Mexico
Prior art keywords
preparation
clomipramine
method therefor
pharmaceutical composition
composition containing
Prior art date
Application number
MX2016008729A
Other languages
English (en)
Inventor
Hyun-Jung Park
Seong-Shin Kwak
Ryeol Jeon Hong
Sang Lee Bong-
Jin LEE Dong-
Hwa KIM Jung-
Original Assignee
Ctc Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctc Bio Inc filed Critical Ctc Bio Inc
Publication of MX2016008729A publication Critical patent/MX2016008729A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una formulación farmacéutica que comprende clomipramina o su sal farmacéuticamente aceptable (preferiblemente, hidrocloruro de clomipramina) como el primer ingrediente activo, y sildenafil o su sal farmacéuticamente aceptable (preferiblemente, citrato de sildenafil) como el segundo ingrediente activo, en donde la estabilidad de la clomipramina es mejorada, y un método para fabricar esta formulación farmacéutica. En particular, la presente invención proporciona una formulación farmacéutica que comprende los dos ingredientes activos anteriores y es fabricada mediante el uso de un método de granulación en húmedo, en donde la estabilidad de la clomipramina es mejorada, y un método para la fabricación de esta formulación farmacéutica.
MX2016008729A 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. MX2016008729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130168702 2013-12-31
PCT/KR2014/012969 WO2015102337A1 (ko) 2013-12-31 2014-12-29 클로미프라민 함유 약학 조성물 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
MX2016008729A true MX2016008729A (es) 2017-02-28

Family

ID=53493626

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008729A MX2016008729A (es) 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX2021000769A MX2021000769A (es) 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000769A MX2021000769A (es) 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.

Country Status (7)

Country Link
US (2) US10045944B2 (es)
EP (1) EP3090732A4 (es)
KR (3) KR20150079449A (es)
CN (1) CN105899193A (es)
BR (1) BR112016015175A2 (es)
MX (2) MX2016008729A (es)
WO (1) WO2015102337A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150079449A (ko) * 2013-12-31 2015-07-08 주식회사 씨티씨바이오 클로미프라민 함유 약학 조성물 및 이의 제조 방법
CN108126203A (zh) * 2018-01-05 2018-06-08 黄平 一种药物组合物及其药物递送系统与用途
US11957692B2 (en) 2022-05-23 2024-04-16 National Institute Of Immunology Clomipramine for the treatment of Alzheimer's Disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US20090118211A1 (en) * 2005-06-27 2009-05-07 Daniel Drai Compositions and Methods for Enhancement of Sexual Function
CA2629904C (en) * 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2009142428A2 (en) * 2008-05-19 2009-11-26 Yuhan Corporation Pharmaceutical composition for the treatment of premature ejaculation
BR112013033475A2 (pt) * 2011-06-28 2017-12-19 Ctc Bio Inc composição farmacêutica para tratamento, prevenção ou melhora da ejaculação precoce e método para tratamento, prevenção ou melhora da ejaculação precoce
KR20150079449A (ko) * 2013-12-31 2015-07-08 주식회사 씨티씨바이오 클로미프라민 함유 약학 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
KR20210104618A (ko) 2021-08-25
KR20220017458A (ko) 2022-02-11
BR112016015175A2 (pt) 2017-08-08
US10512610B2 (en) 2019-12-24
CN105899193A (zh) 2016-08-24
US10045944B2 (en) 2018-08-14
KR102527999B1 (ko) 2023-05-02
US20160324789A1 (en) 2016-11-10
EP3090732A4 (en) 2017-06-28
EP3090732A1 (en) 2016-11-09
KR20150079449A (ko) 2015-07-08
US20180311170A1 (en) 2018-11-01
KR102357423B1 (ko) 2022-02-08
MX2021000769A (es) 2022-07-29
WO2015102337A1 (ko) 2015-07-09

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
SG10201804817TA (en) Delayed release compositions of linaclotide
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MX359288B (es) Forma iv del clorhidrato de ivabradina.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EA201691741A1 (ru) Фармацевтическая композиция
WO2014145314A3 (en) Methods and compositions for gamma-glutamyl cycle modulation
WO2012134187A3 (ko) 황반변성 예방 또는 치료용 약학 조성물
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
WO2013136346A3 (en) Taste masking pharmaceutical orally dissolving strips of lornoxicam
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии